

PA 230806

PCT/GB 00 / 02302
09/926712

REC'D 07 JUL 2000

WIPO PCT

GB00/2302

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 05, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/142,064

FILING DATE: July 02, 1999

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

H. Phillips
H. PHILLIPS
Certifying Officer

COVER SHEET FOR FILING PROVISIONAL PATENT APPLICATION

Box Provisional Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is a request for filing a PROVISIONAL PATENT APPLICATION under 37 C.F.R. 1.53(c).

Docket No.	<u>041565/184080</u>
Type a plus sign (+) inside this box →	+

INVENTOR(S)/APPLICANT(S)

Name: John Walter Liebescheutz
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Alison Mary Johnston
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Amanda Janes Lyons
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Christopher William Murray
Address: Proteus Molecular Design Limited
Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Andrew David Rimmer
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Bohdan Waszkowycz
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Steven Clinton Young
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Nicholas Paul Camp
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Stuart Donald Jones
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Philip John Morgan
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Simon James Richards
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: Jonathan Michael Ernest Roscoe
Address: Proteus Molecular Design Limited
Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

Name: William Alexander Wylie
Address: Proteus Molecular Design Limited
Beechfield House, Lyme Green Business Park
Macclesfield, Cheshire, SK11 0JL England

60143064-070200

TITLE OF THE INVENTION (280 characters maximum)

COMPOUNDS

CORRESPONDENCE ADDRESS

Karen Lee Orzechowski
Registration No. 31,621
ALSTON & BIRD LLP
601 Pennsylvania Avenue, NW
North Building, 11th Floor
Washington, DC 20004-2601
Telephone (202) 756-3371
Facsimile (202) 756-3333

ENCLOSED APPLICATION PARTS (check all that apply)

- ☒ Specification (Number of Pages 44)
☐ Drawing(s) (Number of Sheets)
☐ Claims (Number of Claims)
(A complete provisional application does not require claims 37 C.F.R. § 1.51(a)(2).)
☒ Small Entity Statement (unexecuted)
☒ Other (specify): Assignment (unexecuted)

METHOD OF PAYMENT (check one)

- ☒ Check or money order is enclosed to cover the filing fee.
☐ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 16-0605.
☒ Please charge Deposit Account No. 16-0605 for any fee deficiency.

PROVISIONAL FILING FEE AMOUNT(s)

Large Entity \$150.00
Small Entity \$ 75.00

Filing Fee Amount: \$75.00

041565-184080-070299

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.




No.



Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,



Karen Lee Orzechowski
Registration No. 31,621

Date: July 2, 1999

ALSTON & BIRD LLP
601 Pennsylvania Avenue NW
North Building, 11th Floor
Washington, DC 20004-2601

Telephone (202) 756-3300
Facsimile (202) 756-3333

60142064-070299

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney's Docket No. 041565/184080

Applicant, Patentee, or Identifier: John Walter Liebescheutz et al.
Application No. or Patent No.: To Be Assigned
Filed or Issued: Herewith
Title: Compounds

STATEMENT CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(f) & 1.27(c)) – SMALL BUSINESS CONCERN

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:
☐ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN: Proteus Molecular Design Limited
ADDRESS OF SMALL BUSINESS CONCERN: Beechfield House, Lyme Green Business
Park, Macclesfield, Cheshire SK11 0JL,
England

I hereby state that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. 121.1301-1305, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any

652040-19024109

person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d), or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☐ no such person, concern, or organization exists.
☐ each such person, concern, or organization is listed below.

Name: _____

Address: _____

☐ Individual ☐ Small Business ☐ Nonprofit Organization

Name: _____

Address: _____

☐ Individual ☐ Small Business ☐ Nonprofit Organization

Separate statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

NAME OF PERSON SIGNING: _____

TITLE OF PERSON OTHER THAN OWNER: _____

ADDRESS OF PERSON SIGNING: _____

SIGNATURE: _____ DATE: _____

WDC01/32936v1

70304/002.605

Compounds

5 This invention relates to compounds which are
inhibitors of serine proteases and to pharmaceutical
compositions thereof and their use in the treatment of
the human or animal body.

10 The serine proteases are a group of proteolytic
enzymes which have a common catalytic mechanism
characterized by a particularly reactive Ser residue.
Examples of serine proteases include trypsin, tryptase,
chymotrypsin, elastase, thrombin, plasmin, kallikrein,
Complement C1, acrosomal protease, lysosomal protease,
cocoonase, α -lytic protease, protease A, protease B,
15 serine carboxypeptidase II, subtilisin, urokinase,
Factor VIIa, Factor IXa, and Factor Xa. The serine
proteases have been investigated extensively over a
period of several decades and the therapeutic value of
inhibitors of serine proteases is well understood.

20 Serine protease inhibitors play a central role in
the regulation of a wide variety of physiological
process including coagulation, fibrinolysis,
fertilization, development, malignancy, neuromuscular
patterning and inflammation. It is well known that
25 these compounds inhibit a variety of circulating
proteases as well as proteases that are activated or
released in tissue. It is also becoming clear that
serine protease inhibitors inhibit critical cellular
processes, such as adhesion, migration, free radical
30 production and apoptosis. In addition, animal
experiments indicate that intravenously administered
serine protease inhibitors, variants or cells expressing
serine protease inhibitors, provide a protective effect
against tissue damage.

35 Serine protease inhibitors have also been predicted
to have potential beneficial uses in the treatment of
disease in a wide variety of clinical areas such as

662020-4902105

oncology, neurology, haematology, pulmonary medicine, immunology, inflammation and infectious disease.

In particular serine protease inhibitors may be beneficial in the treatment of thrombotic diseases,
5 asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenosis, atheroma, trauma, shock and reperfusion injury.

Thus for example an inhibitor of Factor Xa has value as a therapeutic agent as an anticoagulant, e.g.
10 in the treatment and prevention of thrombotic disorders. The use of a Factor Xa inhibitor as an anticoagulant is desirable in view of the selectivity of its effect. Many clinically approved anticoagulants have been associated with adverse events owing to the non-specific
15 nature of their effects on the coagulation cascade.

Also, there are well-known associations of $\alpha 1$ protease inhibitor deficiency with emphysema and cirrhosis and C1 esterase inhibitor deficiency with angioedema.

20 We have now found that certain aromatic compounds carrying bulky lipophilic side chains are particularly effective as inhibitors of serine proteases, especially proteases with negatively charged P1 specificity pockets, and most especially the serine proteases
25 thrombin, trypsin, urokinase, Factor VIIa and most importantly Factor Xa. The Factor Xa inhibitors of this invention are potentially useful for the prophylaxis or treatment of thrombotic disorders such as amongst others venous thrombosis, pulmonary embolism, arterial
30 thrombosis, myocardial ischaemia, myocardial infarction, and cerebral thrombosis. They potentially have benefit in the treatment of acute vessel closure associated with thrombolytic therapy and restenosis, e.g. after transluminal coronary angioplasty or bypass grafting of
35 the coronary or peripheral arteries and in the maintenance of vascular access patency in long term hemodialysis patients.

60142064-070299


Factor Xa inhibitors of this invention may, with benefit, form part of a combination therapy with an anticoagulant with a different mode of action or with a thrombolytic agent.

5 We have previously reported in WO99/11657 and WO99/11658 that certain benzamidine and isoquinoline derivatives carrying a bulky lipophilic side chain are excellent inhibitors of serine proteases. Surprisingly, we have now found certain other aromatic compounds also
10 show inhibitory activity against serine proteases, in particular Factor Xa, despite the lack of the amidino or 1-aminoisoquinoline functionality previously believed to be crucial for activity as a factor Xa inhibitor.

The compounds of the invention are thus likely to
15 be available for administration orally. Also, it has been found that the compounds of the invention perform excellently in the prothrombin time assay (PT) when compared to aminoisoquinolines of similar factor Xa activity. The PT assay is a coagulation assay and it is
20 widely accepted that direct acting Factor Xa inhibitors which perform well in the PT assay are more likely to be good antithrombotics.

In WO99/09053 certain 2-aminobenzamide compounds are disclosed as potential motilin receptor antagonists
25 and in US 3268513 similar 2-aminobenzamide compounds are suggested as potential antibacterial agents. However, the novel compounds of the present invention have not before been suggested as potential serine protease inhibitors.

30 Thus viewed from an one aspect the invention provides a serine protease inhibitor compound of formula (I)



- (where R_2 represents a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 or 4 position by halo, nitro, haloalkoxy, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino or R_1 or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_1 , and optionally substituted in the position alpha to the X-X.. group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, alkoxy or alkylthio with the proviso that R_2 cannot be isoquinolyl;
- each X independently is a C, N, O or S atom or a CO, CR_1 , $C(R_1)_2$ or NR_1 group, at least one X being C, CO, CR_1 or $C(R_1)_2$;
- each R_1 independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;
- L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group;
- Y (the α -atom) is a nitrogen atom or a CR_1 group or Y and L taken together form a cyclic group;
- Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, preferably containing 5 to 10 ring atoms and optionally substituted by groups R_3 or phenyl optionally substituted by R_3 ;
- each R_3 independently is R_1 , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylamino-sulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;

662070-49024TDS
E0142064-070299

Lp is a lipophilic organic group, e.g. an alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, oxo, aza, thia, or R₃ groups, preferably a group containing up to 25 carbon atoms;

D is a hydrogen bond donor group; and n is 0, 1 or 2);

or a physiologically tolerable salt thereof, e.g. a halide, phosphate or sulphate salt or a salt with ammonium or an organic amine such as ethylamine or meglumine.

In the compounds of the invention, where the alpha atom is carbon it preferably has the conformation that would result from construction from a D- α -aminoacid NH₂-CR₁(Cy)-COOH where the NH₂ represents part of X-X. Likewise the fourth substituent R₁ at an alpha carbon is preferably a methyl or hydroxymethyl group or hydrogen.

In the compounds of the invention, unless otherwise indicated, aryl groups preferably contain 5 to 10 ring atoms optionally including 1, 2 or 3 heteroatoms selected from O, N and S; alkyl, alkenyl or alkynyl groups or alkylene moieties preferably contain up to 6 carbons, e.g. C₁₋₆ or C₁₋₃; cyclic groups preferably have ring sizes of 3 to 8 atoms; and fused multicyclic groups preferably contain 8 to 16 ring atoms.

The linker group from the R₂ group to the alpha atom is preferably selected from -CH=CH-, -CONH-, -CONR₁-, -NH-CO-, -NH-CH₂-, -CH₂-NH-, -CH₂O-, -OCH₂-, -COO-, -OC=O- and -CH₂CH₂-. Preferably, the X moiety nearest to the alpha atom is an NH or O atom, most preferably a NH group. The X moiety alpha to the aromatic ring is preferably a carbon based group such as CH₂ or CO, preferably CO. Thus a particularly preferred linker X-X is -CONH-. In an alternative embodiment the linker is preferably a -OCH₂- group.

The alpha atom (Y) is preferably a CH or C(CH₃) group, especially CH.


5 The linker group from the alpha atom to the lipophilic group is preferably CO, CH₂NH, CONR₁(CH₂)_m, (CH₂)_mN(R₁)CO(CH₂)_m, (CH₂)_{m+2}, CO(CH₂)_m, (CH₂)_mCO, (CH₂)_mOC=O, (CH₂)_mO, CH=CH(CH₂)_m, SO₂, SO₂NR₁, SO₂(CH₂)_m, (CH₂)_mSO₂ or (CH₂)_mSO₂NR₁ (where each m is independently 0 or 1). The linker may be optionally branched, for example, to incorporate a polar functionality. In a preferred
10 embodiment Y and L taken together form a cyclic group and the alpha atom is therefore a carbon atom. The cyclic group can be unsubstituted or substituted and can have a ring size of from 3 to 8 atoms. Preferably, the cyclic group is a cyclic amide, most preferably wherein
15 the amide nitrogen of the cyclic amide group is bound to the lipophilic group.

The lipophilic group preferably comprises a cycloalkyl, azacycloalkyl, diazacycloalkyl, phenyl, naphthyl, adamantyl, decalinyl, tetrahydrodecalinyl,
20 bicycloalkyl, mono- or diazabicycloalkyl, mono- or bicyclo heteroaromatic or a linear or branched alkyl, alkylene, alkenyl or alkenylene group all optionally substituted by one or more groups R₃, or a combination of at least two such groups linked by a spiro linkage or a
25 single or double bond or by C=O, O, S, SO, SO₂, CONR₁, NR₁-CO-, NR₁ linkage. For example, representative lipophilic groups include a methyl-cyclohexyl, methylcyclohexylmethyl, methylphenylmethyl, phenylethyl, benzylpiperidinyl, benzoylpiperidinyl, bispiperidinyl or
30 phenylpiperazinyl.


Most preferably, the lipophilic group is selected from

60142064-070299

60142064-070299



wherein R_3 is as hereinbefore defined;
 m represents 0 or 1;
 R_4 represents hydrogen, $(CH_2)_wCOOH$, $(CH_2)_wCONH_2$,
 $(CH_2)_wCON\alpha\text{-AminoAcid}$;
 w represents an integer from 0 to 4; and
 X represents CH or N.
 For example specific lipophilic groups include




especially when R_8 represents H, OMe, SO_2Me , F, NO_2 ,
 $SO_2N(R_1)_2$, Cl, OH or a 5 membered heterocyclic group.

30 The hydrogen bond donor group which may be attached
 to the lipophilic group preferably has a nitrogen or
 oxygen atom as the donor atom and conveniently is a
 hydroxyl group, a primary, secondary or tertiary amine,
 or a primary or secondary imine group (as part of an
 35 amidine or guanidine) or a saturated or unsaturated
 heterocyclic group containing a ring nitrogen,
 preferably a group containing 5 to 7 ring atoms. Where

the donor atom is a ring nitrogen, the remote portion of the heterocyclic ring may be part of the lipophilic group.

5 The cyclic group attached to the alpha carbon is preferably an optionally R₃ substituted phenyl, thienyl or naphthyl group.

In one embodiment the aromatic R₂ group is an optionally substituted phenyl, naphthyl, indolyl or isoindolyl group and accordingly, preferred compounds of
10 the invention are of formula (II)



(wherein R₅ is amino, hydroxy or hydrogen, and R₆ and R₇ which may be the same or different represent ,
20 halo, nitro, thiol, cyano, haloalkyl, haloalkoxy, amido, hydrazido, amino, alkylthio, alkenyl, alkynyl or R₁ or taken together form a 5 or 6 membered fused carbocyclic ring or 5 membered heterocyclic ring, which may itself be substituted by R₁, amino, halo, cyano, nitro, thiol,
25 alkylthio, haloalkyl, haloalkoxy.

Ar is an unsubstituted or substituted aryl group, preferably phenyl;

X-X is -CONH-, -CH₂CH₂-, CH₂O-, -COO-, -CH₂NH-, -OCH₂- or -NHCH₂-, especially -CONH-;

30 L₁ is a valence bond or an organic linker group containing 1 to 4 backbone atoms selected from C, N, O and S;

Lp₁ is a cycloalkyl, azacycloalkyl, diazacycloalkyl, phenyl, naphthyl, adamantyl, decalinyl,
35 tetrahydrodecalinyl, bicycloalkyl, mono- or diazabicycloalkyl, mono- or bicyclo heteroaromatic or a linear or branched alkyl, alkylene, alkenyl or


662020-49024TOS

alkenylene group all optionally substituted by a group R_3 , or a combination of at least two such groups linked by a spiro linkage or a single or double bond or by C=O, O, S, SO, SO₂, CONR₁, NR₁-CO-, NR₁ linkage. For example, 5 representative lipophilic groups include a methylcyclohexyl, methylcyclohexylmethyl, bispiperidinyl, methylphenylmethyl, phenylethyl, benzylpiperidinyl, benzoylpiperidinyl or phenylpiperazinyl and those as hereinbefore described;

10 D is a hydrogen bond donor group;
and n is 0, 1 or 2).

In an alternative embodiment the phenyl derivative forming part of the R_2 functionality may instead be a nitrogen heterocyclic group, e.g. pyridine. Thus 15 suitable R_2 groups may be


662020-1902109



60142064-070299

It is preferred that at least one of R_6 and R_7 be other than hydrogen and that R_6 , if present, is preferably a substituent containing one or more polar hydrogens such as hydroxy, amino, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, alkylcarboxyamino, hydrazo and alkylhydrazo; alternatively R_6 and R_7 are joined together in the formation of a naphthyl or indolyl or azaindolyl or diazaindolyl group.

In a further preferred embodiment the compounds of the invention are of formula (A)



(wherein R_5 , R_6 , R_7 , Ar , $X-X$, Lp_1 , D_n are as hereinbefore defined; L_2 is a valence bond or an organic linker group containing 1 to 3 backbone atoms selected from C, N, O and S and R_8 and R_9 are hydrogen or taken together with the carbon atom to which they are attached form a carbonyl group). Again, in an alternative embodiment the phenyl derivative forming part of the R_2 functionality may instead be a nitrogen heterocyclic group, e.g. pyridine.

In one embodiment, L_2 comprises the backbone of an alpha amino acid, the lipophilic group being the side chain of the amino acid. The carboxyl part of the alpha amino acid may be optionally coupled via an amide bond to an amino acid or to a primary or secondary cyclic or acyclic alkyl amine or diamine or via an ester bond to primary or secondary alcohols.

In one preferred embodiment R_8 and R_9 are hydrogen and L_2 is a $OC=O$ or $NHC=O$ group.

In a preferred embodiment, L_2 represents a valence

662020-1902409

bond and the lipophilic group is bound directly to a carbonyl alpha to the alpha atom via a nitrogen atom which forms part of the lipophilic group. Suitable lipophilic groups in this case therefore include

5 piperidinyl, pyrrolidinyl and piperazinyl. In a preferred embodiment the piperidine or piperazinyl group is further substituted by a phenyl, benzyl, phenoxy, piperidine, pyridine or benzoyl group, optionally substituted on the phenyl ring by one or more R_3 groups.

10 In a more preferred embodiment a piperazine is substituted with a phenyl group substituted at the 2-position with an electron withdrawing group such as fluoro, nitro, triazolyl, cyano, alkoxycarbonyl, aminocarbonyl, aminosulphonyl, alkylaminosulphonyl and, especially preferred, alkylsulphonyl; and, at the 4-


15 position, with hydrogen, fluoro, alkoxy or hydroxy. In another more preferred embodiment a piperidine is substituted at the 4-position with 4-piperidine which itself may be substituted on nitrogen by alkyl or aminocarbonylalkyl or alkylaminocarbonyl alkyl.

20

In a further embodiment, the lipophilic group has attached a group of the formula $-COOR_1$ or $-CON$ -aminoacid or ester derivative thereof.

Particularly preferred compounds are those of

25 formula (G)




(wherein Ar, R_6 and R_7 are as hereinbefore defined, R_5 represents hydrogen or amino and ----- represents a

35 cyclic group). Again, in an alternative embodiment the phenyl derivative forming part of the R_2 functionality may instead be a nitrogen heterocyclic group, e.g.

pyridine.

In another embodiment the group binding the alpha carbon atom to the lipophilic group comprises a heterocyclic group. Accordingly, preferred compounds of the invention also include those of formula (III)



(wherein R_5 , R_6 , R_7 , Ar, X-X, Lp_1 , D_n are as hereinbefore defined;

m is 0, 1 or 2;


Het is a 5 or 6-membered heterocyclic group interrupted by 1, 2 or 3 heteroatoms selected from O, N and S optionally substituted by a group R_3). Again, in an alternative embodiment the phenyl derivative forming part of the R_2 functionality may instead be a nitrogen heterocyclic group, e.g. pyridine.

Where Het is a five membered ring, the two ring atoms at which it is connected are preferably separated by one ring atom. Where Het is a six-membered ring, the two ring atoms at which it is connected are preferably separated by one or two ring atoms. Representative heterocyclic groups include thiazole, oxazole, oxadiazole, triazole, thiadiazole or imidazole. Where the heterocyclic group is substituted by R_3 this is preferably a COOH or COOR₁ connected to the heterocycle via a valence bond or alkylene chain.


In a further embodiment, the lipophilic group has attached a group of the formula -COOR₁ or -CON-aminoacid or ester derivative thereof.

In an alternative embodiment the main aromatic R_2 ring in the compounds of the invention is a five membered aromatic ring of formula (IV) or (IVa)


60142064-070299



(wherein R_5 , R_6 , R_7 , $X-X$, Ar , L_1 , Lp_1 , D and n are as
 hereinbefore described for formula (II) and Z represents
 10 N , O or S). It is preferred that at least one of R_6 and
 R_7 be other than hydrogen, or that R_6 and R_7 taken
 together enable the formation of an indolyl, or
 azaindolyl group or diazaindolyl group. Preferences for
 other substituents are as for formula (A) above.
 15 Examples of possible fused systems are given below.




Hence in a preferred embodiment the compounds of
 the invention are of formula C or D



35 (wherein R_5 , R_6 , R_7 , Ar , $X-X$, Z , R_8 , R_9 , L_2 , Lp_1 , D_n are as
 hereinbefore defined) preferences for Ar , $X-X$, R_8 , R_9 , L_2
 Lp_1 , D_n are as for formula (A) above; or compounds of


662020-49224109

formula E or F:



(wherein Lp₁ is connected to the carbonyl via a nitrogen atom, R₆, R₇, Ar, Z, Lp₁, D_n are as hereinbefore defined and R₅ is hydrogen or amino) preferences for Ar, Lp₁, D_n are as for formula (A) above.

The compounds of the invention may be prepared by conventional chemical synthetic routes, e.g. by amide bond formation to couple the aromatic function to the alpha atom and to couple the lipophilic function to the alpha atom. Where the alpha atom is a carbon, the cyclic group-alpha atom combination may conveniently derive from an alpha amino acid with the aromatic deriving from for example an acid derivative of a compound based on R₂, e.g. o-amino-benzoic acid. Amide formation from such reagents (in which any amino or hydroxyl function may if desired be protected during some or all of the synthesis steps) yields a compound of formula (V).




(where Cy and R₂ are as defined above).

The lipophilic group (and optionally simultaneously the hydrogen bond donor) may then conveniently be introduced by reaction of a compound of formula (V) (or another analogous carboxylic acid) optionally after transformation into an activated form, e.g. an acid chloride or active ester, with a lipophilic group carrying an amine, hydroxylamine, hydrazine or hydroxyl group, e.g. to produce compounds with linkages of -CO-

NR₁-, -CO-NR₁-O-, -CO-NR₁-NR₁- and -CO-O- from the alpha atom (where it is a carbon) to the lipophilic group. Where Y and L taken together form a cyclic amide group the lipophilic group can be conveniently introduced by reacting the compound of formula (V) with a lipophilic group carrying a secondary amine with an active side chain. Cyclisation can be base induced via nucleophilic attack of the alpha atom on a leaving group on the active side chain. If necessary the amide linkage can be reduced using an appropriate reducing agent employing the necessary protection depending on whether concurrent reduction of the carboxylic acid moiety is also desired. Alternatively a compound of formula V or another analogous carboxylic acid may be transformed into an alcohol by reaction with isobutylchloroformate and reduction with sodium borohydride.

Such an alcohol, e.g. of formula VI



can be reacted to introduce the lipophilic group by reactions such as:

alkylation with an alkyl halide in the presence of a base;

reaction with diethyl azodicarboxylate/triphenylphosphine and a hydroxylated aryl compound;

by reaction with an activated carboxylic acid (e.g. an acid chloride) or with a carboxylic acid and

diethylazodicarboxylate/triphenylphosphine;

by reaction with an isocyanate; and

by treatment with methanesulphonyl chloride or trifluoromethanesulphonic anhydride and reaction with an amine, or with a thiol optionally followed by oxidation, e.g. with potassium metaperiodate or hydrogen peroxide.

In this way compounds with linkages of -CH₂-O-, -CH₂-O-CO-, -CH₂-O-CO-NR₁-, -CH₂-NR₁-, -CH₂-S-, -CH₂-SO-

50142064-070299

and $-\text{CH}_2-\text{SO}_2-$ between the alpha carbon and the lipophilic group may be produced.

Alternatively the alcohol can be oxidized to form a corresponding aldehyde (e.g. by oxidation with manganese dioxide or DMSO/oxalyl chloride or DMSO/ SO_3 or Dess-Martin reagent) which may be reacted to introduce the lipophilic group by reactions such as:

reaction with Wittig reagents or Horner-Emmons reagents, optionally followed by reduction of the resulting carbon:carbon double bond using H_2/Pd -carbon;

reaction with an organometallic, eg a Grignard reagent, optionally followed by reaction on the resulting hydroxyl group, such as oxidation (eg with MnO_2 , DMSO/oxalyl chloride or Dess-Martin reagent), alkylation (eg with an alkyl halide in the presence of a base in a solvent such as DMF), arylation (eg with diethylazo dicarboxylate/triphenyl phosphine and a hydroxyaryl compound), ester formation (eg with an acid chloride or with a carboxylic acid and diethylazido dicarboxylate/triphenyl phosphine), or carbamate formation (eg with an isocyanate);

by reaction with an amine followed by reduction, e.g. with sodium cyanoborohydride;

by reaction with a hydrazine; or

by reaction with a carbazide.

In this way compounds with linkages of $-\text{CH}=\text{CR}_1-$, $-\text{CH}_2-\text{CHR}_1-$, $-\text{CHOH}-$, $-\text{CHR}_1-\text{O}-$, $-\text{CHR}_1-\text{O}-\text{CO}-$, $-\text{CHR}_1-\text{O}-\text{CO}-\text{NR}_1-$, $-\text{CO}-$, $-\text{CH}_2-\text{NR}_1-$, $-\text{CH}=\text{N}-\text{NR}_1-$ and $-\text{CH}=\text{N}-\text{NR}_1-\text{CO}-\text{NR}_1-$ between the alpha carbon and the lipophilic group may be produced.


The transformation of alcohol to amine referred to above may be used to produce an amine reagent for lipophilic group introduction, e.g. a compound $\text{R}_2-\text{CONH}-\text{CH}(\text{Cy})-\text{CH}_2-\text{NR}_1\text{H}$.

Such an amine reagent may be reacted to introduce the lipophilic group, e.g. by acylation with an acid halide or activated ester, by reaction with isocyanate,

by reaction with an isothiocyanate, or by reaction with a sulphonyl chloride. In this way compounds with linkages of $-\text{CH}_2\text{NR}_1-\text{CO}-$, $-\text{CH}_2-\text{NR}_1-\text{CO}-\text{NR}_1-$, $-\text{CH}_2\text{NR}_1-\text{CS}-\text{NR}_1-$ and $-\text{CH}_2\text{NR}_1-\text{SO}_2-$ between the alpha carbon and the lipophilic groups may be produced.


The transformation of acid to amide referred to above may be used to produce an amide reagent for introduction of the lipophilic group, e.g. a compound $\text{R}_2-\text{CONH}-\text{CH}(\text{Cy})-\text{CON}(\text{R}_1)_2$.

Such amides may be reacted to introduce lipophilic groups, e.g. by reaction with a haloketone (e.g. phenacyl bromide). This provides a linkage




from alpha carbon to lipophilic group.


Analogously the amide may be transformed to a thioamide by reaction with Lawesson's reagent and then reacted with a haloketone to form a linkage



The amide reagent may likewise be transformed to a nitrile reagent by dehydration, e.g. with trifluoroacetic anhydride. The nitrile reagent may be reacted with hydrazine then with acyl halide and then cyclized, (e.g. with trifluoroacetic anhydride) to produce a linkage




Alternatively it may be treated with hydroxylamine then reacted with acyl halide and cyclized (e.g. with trifluoroacetic anhydride) to produce a linkage



5 The hydrazide produced by reaction of a carboxylic acid reagent with hydrazine discussed above may likewise be used as a reagent for lipophilic group introduction, e.g. as a compound of formula $R_2\text{-CONH-CH(Cy)-CO-NR}_1\text{-N(R}_1)_2$.

10 Thus the hydrazide reagent can be reacted with an acyl halide and cyclized, e.g. with trifluoroacetic anhydride to yield a linkage




15

or reacted with an acyl halide or an isocyanate to yield linkages $\text{-CO-NR}_1\text{-NR}_1\text{-CO-}$ and $\text{-CO-NR}_1\text{-NR}_1\text{-CO-NR}_1\text{-}$ respectively.


20 Alternatively the hydrazide may be transformed by reaction with Lawesson's reagent and then reacted with an acyl halide and cyclized (e.g. with trifluoroacetic anhydride) to produce the linkage

25



30 An alternative route to these compounds is to carry out any of the above chemical reactions to incorporate the lipophilic group (an optional H bond donor) into a protected intermediate such as a compound of formula (VII).

35




PG=Protecting group

662020-49024709

The protecting group may then be removed before coupling of the for example o-amino benzoic acid (optionally protected).

5 A starting reagent for lipophilic group introduction where the alpha atom is nitrogen may be produced for example by reaction of a beta protected hydrazine (such protection to be chosen as to be compatible with the subsequent reagents to be employed) with phosgene, diphosgene, triphosgene or N,N'carbonyl
10 diimidazole to give a reactive compound of the type:



15

PG = Protecting group


This intermediate may be used as has been described above for the carboxylic starting reagents where the
20 alpha atom is carbon.

Removal of the protecting group by standard methods and coupling with an activated aryl carboxylic acid will give compounds of the type

25
$$\text{R}_2-\text{CONH}-\text{N}(\text{Cy})-\text{L}-\text{Lp}(\text{D})_n$$

(where R_2 , X, Y, Cy, L, Lp and D are as defined above).

Thus viewed from a further aspect the invention provides a process for the preparation of a compound according to the invention which process comprises
30 coupling a lipophilic group to a compound of formula (VIII)



(wherein R_2 , X, Y and Cy are as defined above and Z_1 is a
35 reactive functional group), and optionally subsequently coupling a hydrogen bond donor group to said lipophilic group.

60142064.020299

5 The compounds of the invention may be administered
by any convenient route, e.g. into the gastrointestinal
tract (e.g. rectally or orally), the nose, lungs,
musculature or vasculature or transdermally. The
10 compounds may be administered in any convenient
administrative form, e.g. tablets, powders, capsules,
solutions, dispersions, suspensions, syrups, sprays,
suppositories, gels, emulsions, patches etc. Such
compositions may contain components conventional in
15 pharmaceutical preparations, e.g. diluents, carriers, pH
modifiers, sweeteners, bulking agents, and further
active agents. Preferably the compositions will be
sterile and in a solution or suspension form suitable
for injection or infusion. Such compositions form a
further aspect of the invention.

20 Viewed from this aspect the invention provides a
pharmaceutical composition comprising a serine protease
inhibitor according to the invention together with at
least one pharmaceutically acceptable carrier or
excipient. The pharmaceutical composition may also
optionally comprise at least one further antithrombotic
and/or thrombolytic agent.

25 Viewed from a further aspect the invention provides
the use of a serine protease inhibitor according to the
invention for the manufacture of a medicament for use in
a method of treatment of the human or non-human animal
body (e.g. a mammalian, avian or reptilian body) to
combat (i.e. treat or prevent) a condition responsive to
said inhibitor.

30 Viewed from a further aspect the invention provides
a method of treatment of the human or non-human animal
body (e.g. a mammalian, avian or reptilian body) to
combat a condition responsive to a serine protease
inhibitor (e.g. a condition such as a thrombotic
35 disorder responsive to a factor Xa inhibitor), said
method comprising administering to said body an
effective amount of a serine protease inhibitor

50142064-070299

according to the invention.

The dosage of the inhibitor compound of the invention will depend upon the nature and severity of the condition being treated, the administration route and the size and species of the patient. However in general, quantities of from 0.01 to 100 $\mu\text{mol/kg}$ bodyweight will be administered.

All publications referred to herein are hereby incorporated by reference.

The invention will now be described further with reference to the following non-limiting Examples.

Experimental

Abbreviations used follow IUPAC-IUB nomenclature. Additional abbreviations are Hplc, high-performance liquid chromatography; DMF, dimethylformamide; DCM, dichloromethane; HAOT, 1-hydroxy-7-azabenzotriazole; HATU, [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate]; Fmoc, 9-Fluorenylmethoxycarbonyl; HOBt, 1-hydroxybenzotriazole; TBTU, 2-(1H-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate; EDCI, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DIPEA, diisopropylethylamine; Boc, tertiary butyloxycarbonyl; DIPCI, diisopropylcarbodiimide; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; TEA, triethylamine; Rink linker, p-[(R,S)- α -[1-(9H-Fluoren-9-yl)methoxyformamido]-2,4-dimethoxybenzyl]phenyl acetic acid; TFA, trifluoroacetic acid; MALDI-TOF, Matrix assisted laser desorption ionisation - time of flight mass spectrometry, RT, retention time. Unless otherwise indicated amino acid derivatives, resins and coupling reagents were obtained from Novabiochem (Nottingham, UK) and other solvents and reagents from Rathburn (Walkerburn, UK) or Aldrich (Gillingham, UK) and were used without further purification. All solution

60142064-070299

concentrations are expressed as %Vol./%Vol. unless otherwise stated.

5 Purification: Purification was by gradient reverse phase
Hplc on a Waters Deltaprep 4000 at a flow rate of 50 ml/
min. using a Deltapak C18 radial compression column (40
mm x 210 mm, 10-15 mm particle size). Eluant A
consisted of aqTFA (0.1%) and eluant B 90% MeCN in
10 aqTFA(0.1%) with gradient elution (Gradient 1, 0 min.
20%B then 20% to 100% over 36 min., Gradient 2, 0 min.
5%B for 1 min., then 5%B to 20%B over 4 min., then 20%
to 60% over 32 min. or Gradient 3, 0 min. 20%B then 20%
to 100% over 15 min.). Fractions were analysed by
15 analytical Hplc and MALDI-TOF before pooling those with
>95% purity for lyophilisation.

20 Analysis: Analytical Hplc was on a Shimadzu LC6
gradient system equipped with an autosampler, a variable
wavelength detector at flow rates of 0.4 ml/ min.
Eluents A and B as for preparative Hplc . Columns used
were Techogell15 C18 (2x150mm) (Hplc Technology), Magellan
C8 column (2.1x150 mm, 5µm particle size)
(Phenomenex)) Purified products were further analysed by
MALDI-TOF and nmr.

25

Synthesis of inhibitors

Method 1: Using a solid phase strategy on a Protein
Technologies, Symphony Multiple Peptide Synthesiser by
30 attachment of bis amino compounds to Peg-trityl
chloride resin: Trityl chloride resin was typically
treated with greater than 2 fold excess of the di-amine
in dry DCM .The resin was further modified by the
attachment of acids. Activation of Fmoc protected amino
35 acid (2-Seq) was by TBTU/ DIPEA, all couplings (minimum
120 min.) were carried out in DMF. Deprotection of the
Fmoc group was achieved with 20% piperidine in DMF. In

the next stage other acid substituents were added as the
HOBt or HOAt esters either by activation with HBTU/HATU
or HATU/EDCI with or without Boc protection of amino
groups. Cleavage of the products from the resin was by
5 treatment (30 min., ambient) with 10% triethylsilane in
TFA, filtration, evaporation and trituration with
diethylether.

Synthesis using the Symphony Multiple Peptide
10 Synthesiser.

The Symphony Multiple Peptide Synthesiser is charged
with DMF, DCM, TBTU in DMF (450 mM), DIPEA in DMF (900
mM), 20% piperidine in DMF. Resins are held in plastic
15 reaction vessels that allow the introduction of reagents
and solvents and nitrogen for agitation or air drying.

A typical synthesis cycle on the Symphony is as
follows:-

20 The reaction vessel containing the resin (0.1 mmol) is
charged with the Fmoc protected amino acid (0.5 mmol)
and then this is dissolved in DMF (2.5ml), treated with
TBTU (0.56 mmol, 1.25ml) and DIPEA (1.1 mmol, 1.25ml)
25 and agitated with nitrogen for 2 hours (agitation times
may vary). After coupling the resin is washed with DMF
(6x 5ml) then deprotected with 20% piperidine in DMF (2x
5ml for 1 min.each, then 1x 5ml for 8 min.) the resin is
then washed with DMF (6x 5ml).

30

Example 1.

**2-Amino-4-chlorobenzoyl-D-phenylglycine
4,4'bispiperidinamide**

35 4,4-Bipiperidine.dihydrochloride (4mmol, 1g) was
dissolved in water (5ml) and 2M sodium hydroxide
solution (10mmol, 5ml) added. The solution was extracted

662020-19024T09

with ethylacetate (2x 50ml) the combined extracts were washed with water, dried over anhydrous sodium carbonate, filtered and evaporated to give the 4,4 bipiperidine (0.35g) as a white solid. The 4,4 bipiperidine was dissolved in dry DMF (2ml) and added to Peg-tritylchloride resin (0.95 mmol/g, 1.5g) pre swollen in dry DCM (10ml). After 2h the resin was washed with DCM (6x5ml), DMF (6x5ml) and DCM (6x5ml). The resin was then air dried to allow aliquots to be taken.

The 4,4 bipiperidine trityl resin (0.1 mmol) was treated with Fmoc-D-Phenylglycine (0.5 mmol, 187mg), DMF (2.5ml), TBTU in DMF (1.25ml of a 450mM solution) and DIPEA in DMF (1.25ml of a 900 mM solution). The mixture was agitated with nitrogen for 2 hours. Deprotection and washing as above.

A solution of 4-chloroanthranilic acid (87mg 0.5mmole) in dry dimethylformamide (DMF) was treated successively with HOAt (102mg 0.75mmole) and EDCI (115mg 0.6mmole) and stirred at room temperature for 10min. The mixture was transferred to the reaction vessel on the Symphony and agitated for 2 hours with nitrogen. The resin was washed with DMF (6x5ml), DCM (6x5ml) and air dried. The product was cleaved from the resin with 10% triethylsilane in TFA (10ml) for 30 minutes, the resin filtered off and the TFA solution evaporated to dryness and triturated with diethyl ether to give the crude product. The crude product was dissolved in water (10ml), filtered and purified by preparative reverse phase Hplc.

¹H nmr (CD₃CN) 7.30 (6H,m); 6.60 (1H,s); 6.55 (1H,d); 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m) MS TOF 456 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.77 min.

Example 2.

2-Amino-5-bromobenzoyl-D-phenylglycine

4,4'bispiperidinamide

¹H nmr (CD₃CN) 7.30 (7H,m); 6.50 (1H,d); 5.85 (1H, s);
5 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H,
m); 1.10 (6H, m) MS TOF 500 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 11.31 min.

Example 3.

2-Amino-4-methylbenzoyl-D-phenylglycine

10 **4,4'bispiperidinamide**

¹H nmr (CD₃CN) 7.30 (6H,m); 6.50 (1H,s); 6.45 (1H,d);
5.80 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H,
m); 2.05 (3H,s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 436
15 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.22 min.

Example 4.

2-Amino-5-methylbenzoyl-D-phenylglycine

4,4'bispiperidinamide

¹H nmr (CD₃CN) 7.30 (7H,m); 6.50 (1H,d); 5.85 (1H, s);
20 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H,
m); 1.10 (6H, m). MS TOF 436 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 8.74 min.

Example 5.

2-Amino-5-methoxybenzoyl-D-phenylglycine

25 **4,4'bispiperidinamide**

¹H nmr (CD₃CN) 7.55 (6H,m); 7.30 (1H,d); 6.95 (1H,m);
6.15 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 3.60 (3H, s);
2.30-2.95 (6H, m); 2.20 (3H, s); 1.60 (4H, m); 1.10 (6H,
m) MS TOF 452 (M+1⁺). Hplc (Magellan C8, Gradient 3,
30 water/acetonitrile/TFA) rt 8.20 min.

Example 6.

2-Dimethylaminobenzoyl-D-phenylglycine

4,4'bispiperidinamide

¹H nmr (CD₃CN) 7.80 (1H,d); 7.65 (2H,m); 7.30 (6H,m);
35 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 3.10 (6H, s);
2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m) MS TOF 450
(M+1⁺). Hplc (Magellan C8, Gradient 3,

062020-49024709

water/acetonitrile/TFA) rt 9.57 min.

Example 7.

3-Methylbenzoyl-D-phenylglycine 4,4'bispiperidinamide

¹H nmr (CD₃CN) 7.40 (2H,m); 7.30 (7H,m); 5.85 (1H, s);
5 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 2.20 (3H,
s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 421 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
10.68 min.

Example 8.

10 **4-Methylbenzoyl-D-phenylglycine 4,4'bispiperidinamide**

¹H nmr (CD₃CN) 7.55 (2H,m); 7.30 (5H,m); 7.10 (2H,m);
5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H,
m); 2.20 (3H,s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 420
(M+1⁺). Hplc (Magellan C8, Gradient 3,
15 water/acetonitrile/TFA) rt 10.61 min.

Example 9.

3-Amino-2-naphthoyl-D-phenylglycine

4,4'bispiperidinamide

¹H nmr (CD₃CN) 7.90 (1H,d); 7.60 (1H,d); 7.40 (1H,m);
20 7.30 (6H,m); 7.05 (1H,m); 6.90 (1H,s); 5.85 (1H, s);
4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H,
m); 1.10 (6H, m) MS TOF 471 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 9.87 min.

Example 10.

25 **3-Aminobenzoyl-D-phenylglycine 4,4'bispiperidinamide**

MS TOF 421 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.06 min.

Example 11.

2-Aminobenzoyl-D-phenylglycine 4,4'bispiperidinamide

30 MS TOF 421 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.00 min.

Example 12.

2-Amino-4-fluorobenzoyl-D-phenylglycine

4,4'bispiperidinamide

35 MS TOF 440 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.23 min.

Example 13.

062020-19024709

2-Amino-5-fluorobenzoyl-D-phenylglycine
4,4'bispiperidinamide

MS TOF 440 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.14 min.

5 **Example 14.**

2-Amino-4-nitrobenzoyl-D-phenylglycine
4,4'bispiperidinamide

MS TOF 467 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 10.59 min.

10 **Example 15.**

2-Amino-5-nitrobenzoyl-D-phenylglycine
4,4'bispiperidinamide

MS TOF (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 10.57 min.

15 **Example 16.**

2-Amino-4,5-dimethoxybenzoyl-D-phenylglycine
4,4'bispiperidinamide

MS TOF 481 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 11.67 min.

20 **Example 17.**

Benzoyl-D-phenylglycine 4,4'bispiperidinamide

MS TOF 407 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.88 min.

Example 18.

25 4-Chlorobenzoyl-D-phenylglycine 4,4'bispiperidinamide

MS TOF 441 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 10.89 min.

Example 19.

2-Hydroxybenzoyl-D-phenylglycine 4,4'bispiperidinamide

30 MS TOF 423 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 8.97 min.

Method 2: By solution phase strategy: Typically an
activated Boc-amino acid was treated with an amine
35 (primary or secondary) or alcohol (1eq.). Activation of
Boc protected amino acid was by HATU or TBTU/
DIPEA(1:2), all couplings (minimum 120 min.) were

carried out in DMF. After an aqueous work up the deprotection of the Boc group was achieved with TFA. Other acid substituents were added as the HOBt or HOAt esters either by activation with HBTU/HATU, EDC or DIPCI with or without Boc protection of amino groups. The final products were purified by preparative reverse phase Hplc.

Example 20.

3-Hydroxymethylbenzoyl-D-phenylglycine-4-methylbenzylamide

Boc D-phenylglycine (251 mg, 1 mmol.) was dissolved in DMF (3ml) with HATU (380 mg., 1 mmol.) and DIPEA (350 μ l., 2 mmol.). To this mixture was added 4-methylbenzylamine (121mg., 1 mmol.) and DIPEA (170 μ l., 1 mmol.). The mixture was stirred overnight. The mixture was then taken up into ethylacetate and washed with water, sodium carbonate solution, water, 10% hydrochloric acid solution and water. The ethylacetate was evaporated without drying and treated immediately with TFA for 30 min. The TFA was then evaporated to dryness and the product triturated with diethylether. TEA (1ml) was added and evaporated to dryness. A solution of 3-hydroxymethylbenzoic acid (76mg, 0.5mmole) in dry dimethylformamide (DMF) was treated with TBTU (161mg., 0.5mmol.) and DIPEA (1.5 mmol.). The mixture was then added to the D-phenylglycine-4-methylbenzylamide (0.5mmol.) and stirred overnight. The crude product was dissolved in water/acetonitrile (20ml), filtered and purified by preparative Hplc to yield pure product.

^1H nmr (CD_3CN) 7.75 (1H, m); 7.65 (2H, m); 7.30 (7H, broad m); 6.80 (3H, m); 5.40 (1H, s); 4.45 (2H, s); 4.10 (2H, m); 2.10 (3H, s). MS TOF 389 ($\text{M}+1$). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 13.51 min.

Compounds made by the above method:-

Example 21.

3-Hydroxybenzoyl-D-phenylglycine-4-methylbenzylamide

¹H nmr (CD₃CN) 7.75 (1H, m); 7.40 (2H, m); 7.30 (5H, broad m); 6.95 (5H, m); 5.40 (1H, s); 4.20 (2H, m); 2.20 (3H, s). MS TOF 375 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.28 min.

Example 22.

3-Aminobenzoyl-D-phenylglycine-4-methylbenzylamide

¹H nmr (CD₃CN) 7.70-7.30 (13H, broad m); 5.65 (1H, s); 4.35 (2H, m); 2.25 (3H, s). MS TOF 374 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 10.44 min.

Example 23.

3-Amidobenzoyl-D-phenylglycine-4-methylbenzylamide

¹H nmr (CD₃CN) 8.40 (1H, m); 8.20 (2H, m); 7.60 (6H, broad m); 7.20 (4H, m); 5.75 (1H, s); 4.50 (2H, m); 2.40 (3H, s). MS TOF 402 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.16 min.

Example 24.

3-Aminomethylbenzoyl-D-phenylglycine-4-methylbenzylamide

¹H nmr (CD₃CN) 7.80 (2H, m); 7.45 (5H, m); 7.30 (2H, m); 6.95 (4H, m); 5.55 (1H, s); 4.25 (2H, s); 4.05 (2H, s); 2.20 (3H, s). MS TOF 388 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.28 min.

Example 25.

3-Amidobenzoyl-D-phenylglycine-4-(aminomethyl)benzylamide

¹H nmr (CD₃CN) 8.20 (1H, s); 7.95 (2H, m); 7.60 (1H, m); 7.30 (5H, broad m); 6.95 (5H, m); 5.40 (1H, s); 4.20 (2H, m); 2.20 (3H, s). MS TOF 417 (M+1⁺). Hplc (Magellan C8, Gradient 2, water/acetonitrile/TFA) rt 14.05 min.

Example 26.

3-Aminomethylbenzoyl-D-phenylglycine-4-aminomethylcyclohexyl methylamide

¹H nmr (CD₃CN) 7.95 (2H, m); 7.80 (2H, m); 7.50 (5H, m); 5.65 (1H, s); 4.45 (2H, s); 3.30 (2H, m); 3.00 (2H, m); 2.00-1.00 (10H, m). MS TOF 409 (M+1⁺). Hplc (Magellan C8,

662070-1902409

Gradient 3, water/acetonitrile/TFA) rt 12.68 min.

Exempl 27.

2-Amino-N-[1-(ethoxycarbonyl)-1-

(phenyl)methyl]benzimidazole-5-carboxamide

5 ¹H nmr (CD₃CN) 7.80 (1H, s); 7.55 (1H, d); 7.40 (5H, m);
7.20 (1H, d); 5.85 (1H, s); 4.15 (2H, m); 1.25 (3H, m).
MS TOF 339 (M+1⁺). Hplc (Magellan C8, Gradient 2,
water/acetonitrile/TFA) rt 17.05 min.

Example 28.

10 **3-Aminomethylbenzoyl-D-phenylglycine-1-adamantylamide**

¹H nmr (CD₃CN) 7.95 (1H, s); 7.85 (2H, d); 7.60 (1H, m);
7.50 (2H, m); 7.40 (3H, m); 5.65 (1H, s); 4.20 (2H, s);
2.50-1.50 (15H, m). MS TOF 418 (M+1⁺). Hplc (Magellan C8,
Gradient 1, water/acetonitrile/TFA) rt 18.36 min.

15 **Example 29.**

**2-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-
methylsulphonylphenyl)piperazinamide**

20 ¹H nmr (DMSO) 7.65 (3H, m); 7.45 (1H, m); 7.35 (5H,
m); 7.15 (1H, m); 6.65 (1H, d); 6.55 (1H, m); 6.05 (1H, s);
3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 511 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
13.43 min.

Example 30.

25 **2-Amino-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-
methylsulphonylphenyl)piperazinamide**

¹H nmr (DMSO) 7.55 (3H, m); 7.45 (1H, m); 7.35 (5H,
m); 7.15 (1H, m); 6.75 (1H, s); 6.55 (1H, d); 6.05 (1H, s);
3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 546 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
30 15.18 min.

Example 31.

**2-Amino-5-fluorobenzoyl-D-phenylglycine-N-(4-fluoro-2-
methylsulphonylphenyl)piperazinamide**

35 ¹H nmr (CDCl₃) 7.75 (1H, m); 7.60 (1H, m); 7.25 (6H,
m); 7.15 (1H, m); 6.90 (1H, m); 6.75 (1H, m); 5.85 (1H, s);
3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 529 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt

662020-49024105

13.87 min.

Example 32.

2-Amino-4-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

5 ¹H nmr (DMSO) 7.55 (3H, m); 7.45 (2H, m); 7.35 (5H, m); 6.65 (1H, s); 6.35 (1H, d); 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m) 2.15 (3H, s);. MS TOF 525 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 13.12 min.

10 **Example 33.**

2-Amino-5-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 7.75 (1H, m); 7.60 (1H, m); 7.25 (6H, m); 7.15 (1H, m); 6.90 (1H, m); 6.75 (1H, m); 5.85 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m) 2.30 (3H, s). MS TOF 525 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.84 min.

Example 34.

2-Amino-4-nitrobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

20 ¹H nmr (CDCl₃) 7.75 (2H, m); 7.55 (1H, m); 7.35 (7H, m); 7.25 (1H, m); 5.80 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 556 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.35 min.

25 **Example 35.**

2-Amino-5-nitrobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 8.25 (1H, d); 7.85 (1H, m); 7.55 (1H, m); 7.25 (7H, m); 7.05 (1H, m); 5.80 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 556 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.08 min.

Example 36.

2-Amino-5-cyanobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

35 ¹H nmr (CD₃CN) 7.65 (4H, m); 7.25 (6H, m); 6.65 (1H, d); 5.80 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 536 (M+1⁺). Hplc (Magellan C8, Gradient 3,

662020-4902409

water/acetonitrile/TFA) rt 14.89 min.

Example 37.

2,5-Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

5 ¹H nmr (CDCl₃) 7.70 (1H, d); 7.45 (7H, m); 6.85 (1H, s); 6.55 (1H, m); 6.55 (1H, m); 5.90 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 526 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.82 min.

Example 38.

10 **2-Amino-4,5-dimethoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

¹H nmr (CD₃CN) 7.65 (2H, m); 7.35 (2H, m); 7.25 (5H, m); 6.75 (1H, d); 6.15 (1H, d); 5.80 (1H, s); 3.60 (3H, s); 3.50 (3H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 571 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.84 min.

Example 39.

Benzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

20 ¹H nmr (CD₃CN) 7.75 (2H, m); 7.70 (1H, m); 7.40 (10H, m); 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 496 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.84 min.

Example 40.

25 **2-Methylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

¹H nmr (CD₃CN) 7.75 (1H, m); 7.65 (1H, d); 7.50 (1H, d); 7.45 (2H, m); 7.30 (5H, m); 6.80 (1H, d); 6.70 (1H, m); 6.00 (1H, s); 3.15 (3H, s); 2.80 (3H, s); 3.00-2.00 (8H, m). MS TOF 525 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 14.63 min.

Example 41.

2-Dimethylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

35 ¹H nmr (CD₃CN) 7.85 (1H, d); 7.50 (2H, m); 7.45 (3H, m); 7.30 (6H, m); 6.00 (1H, s); 3.15 (3H, s); 2.80 (6H, s); 3.00-2.00 (8H, m). MS TOF 539 (M+1⁺). Hplc (Magellan C8,

662020-19024109

Gradient 3, water/acetonitrile/TFA) rt 12.58 min.

Example 42.

3-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

5 ¹H nmr (CD₃CN) 7.85 (1H, m); 7.60 (1H, m); 7.50 (2H, m);
7.30 (7H, m); 7.05 (1H, d); 6.05 (1H, s); 3.15 (3H,s);
3.00-2.00 (8H,m). MS TOF 511 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 11.32 min.

Example 43.

10 **4-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

¹H nmr (CDCl₃) 7.95 (1H, d); 7.80-7.45 (10H, broad m);
7.35 (1H,d); 6.20 (1H, s); 3.15 (3H,s); 3.00-2.00
15 (8H,m). MS TOF 511 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 12.05 min.

Example 44.

3,4 Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 7.75 (1H, d); 7.40-7.15 (9H, broad m);
20 6.55 (1H,d); 6.00 (1H, s); 3.15 (3H,s); 3.00-2.00
(8H,m). MS TOF 540 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 11.30 min.

Example 45.

3-Chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

25 ¹H nmr (CD₃CN) 7.85 (1H, m); 7.80 (1H, s); 7.60 (2H, m);
7.30 (8H, m); 6.00 (1H, s); 3.20 (3H,s); 3.00-2.00
(8H,m). MS TOF 531 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 15.40 min.

30 **Example 46.**

4-Chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.95 (1H, m); 7.75 (2H, m); 7.60 (1H, m);
7.40 (8H, m); 6.05 (1H, s); 3.25 (3H,s); 3.00-2.00
35 (8H,m). MS TOF 531 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 16.54 min.

662020"49024T09
60142064"070209

Example 47.

3-Amino-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 8.05 (1H, m); 7.80 (1H, m); 7.70 (1H, s);
5 7.20-7.60 (8H, broad m); 6.05 (1H, s); 3.25 (3H, s);
3.00-2.00 (8H, m). MS TOF 546 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 14.53 min.

Example 48.

4-Bromobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.85 (1H, m); 7.65 (2H, m); 7.60 (2H, d);
10 7.45 (2H, d); 7.30 (5H, m); 6.00 (1H, s); 3.20 (3H, s);
3.00-2.00 (8H, m). MS TOF 576 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 15.94 min.

Example 49.

4-Iodobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.75 (2H, m); 7.65 (1H, m); 7.55 (2H, d);
15 7.45 (2H, d); 7.30 (5H, m); 5.95 (1H, s); 3.20 (3H, s);
20 3.00-2.00 (8H, m). MS TOF 622 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 15.96 min.

Example 50.

3-Amino-4-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 7.95 (1H, s); 7.60 (1H, d); 7.45 (1H, d);
25 7.40-7.15 (8H, broad m); 6.00 (1H, s); 3.15 (3H, s);
3.00-2.50 (8H, m); 2.20 (3H, s). MS TOF 525 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
11.71 min.

Example 51.

4-Methoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.85 (2H, d); 7.65 (1H, m); 7.50 (2H, m);
35 7.40 (5H, m); 6.80 (2H, d); 6.00 (1H, s); 3.80 (3H, s);
3.20 (3H, s); 3.00-2.00 (8H, m). MS TOF 526 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
14.63 min.

60142064-070299

Example 52.

3-Amino-4-methoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

¹H nmr (CDCl₃) 7.90 (1H, m); 7.75 (1H, d); 7.60 (2H, m);
5 7.40-7.15 (6H, broad m); 7.45 (1H, d); 6.10 (1H, s);
3.95 (3H, s); 3.35 (3H, s); 3.00-2.50 (8H, m). MS TOF 541
(M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 11.78 min.

Example 53.

10 **3,4-Dihydroxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

¹H nmr (CDCl₃) 7.55 (1H, m); 7.45 (1H, d); 7.25 (2H, m);
7.15 (5H, m); 7.00 (1H, d); 6.60 (1H, d); 5.80 (1H, s);
3.05 (3H, s); 3.00-2.50 (8H, m). MS TOF 541 (M+1⁺). Hplc
15 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
11.78 min.

Example 54.

Naphth-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

20 ¹H nmr (CDCl₃) 8.35 (1H, s); 8.00 (1H, d); 7.85 (5H, m);
7.45 (4H, m); 7.25 (4H, m); 6.10 (1H, s); 3.20 (3H, s);
3.00-2.50 (8H, m). MS TOF 546 (M+1⁺). Hplc (Magellan C8,
Gradient 3, water/acetonitrile/TFA) rt 16.66 min.

Example 55.

25 **3-Aminonaphth-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

¹H nmr (CDCl₃) 8.15 (1H, d); 8.00 (1H, s); 7.75 (2H, m);
7.65 (1H, d); 7.30 7.60 (9H, m); 6.10 (1H, s); 3.25
(3H, s); 3.00-2.50 (8H, m). MS TOF 561 (M+1⁺). Hplc
30 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
13.90 min.

Example 56.

Thiophene-3-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

35 ¹H nmr (CDCl₃) 8.15 (1H, s); 7.95 (1H, m); 7.85 (1H, m);
7.60 (8H, m); 6.30 (1H, s); 3.45 (3H, s); 2.00-2.50
(8H, m). MS TOF 502 (M+1⁺). Hplc (Magellan C8, Gradient

662020 49024109

3, water/acetonitrile/TFA) rt 14.28 min.

Thiophene-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

Example 58.

¹H nmr (CDCl₃) 7.70 (1H, m); 7.45 (2H, m); 7.35 (6H, m); 6.65 (1H, m); 6.00 (1H, s); 3.05 (3H, s); 3.00-2.50 (8H, m) 2.45 (3H, s). MS TOF 516 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 14.98 min.

Example 59.

¹H nmr (CD₃CN) 9.50 (1H, s); 8.75 (1H, s); 8.55 (1H, d);
20 8.30 (1H, d); 8.10 (2H, m); 7.65 (1H, m); 7.45 (2H, m);
7.35 (5H, m); 6.10 (1H, s); 3.20 (3H, s); 3.00-2.50
(8H, m). MS TOF 547 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 11.39 min.

Example 60.

¹H nmr (CD₃CN) 9.00 (1H, s); 8.70 (1H, d); 8.35 (1H, d);
8.10 (1H, m); 7.65 (2H, m); 7.45 (1H, m); 7.30 (5H, m);
6.00 (1H, s); 3.20 (3H, s); 3.00-2.50 (8H, m). MS TOF 497
30 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 11.99 min.

Example 61.

35 ¹H nmr (CD₃CN) 7.95 (2H, m); 7.60 (2H, m); 7.50 (3H, m);
7.35 (5H, m); 6.45 (1H, s); 6.05 (1H, s); 3.25 (3H, s);
3.00-2.50 (8H, m). MS TOF 535 (M+1⁺). Hplc (Magellan C8,

Gradient 3, water/acetonitrile/TFA) rt 15.44 min.

Example 62.

2,4-Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

- 5 MS TOF 526 (M+1⁺). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.89 min.

Assay protocols

10 **Enzyme Inhibition assays:**

Enzyme assays were carried out at room temperature in 0.1M phosphate buffer, pH7.4 according to the method of Tapparelli et al (J. Biol. Chem. 1993,268,4734-4741).

- 15 Purified human factor Xa, trypsin, thrombin and plasmin were purchased from Alexis Corporation, Nottingham, UK. Urokinase was purchased from Calbiochem, Nottingham, UK. Chromogenic substrates for these enzymes; pefachrome-FXA, pefachrome-TRY, pefachrome-TH, pefachrome-PL and
- 20 pefachrome-UK were purchased from Pentapharm AG, Basel, Switzerland. Product (p-nitroaniline) was quantified by adsorption at 405nm in 96 well microplates using a Dynatech MR5000 reader (Dynex Ltd, Billingshurst, UK). Km and Ki were calculated using SAS PROC NLIN (SAS
- 25 Institute, Cary, NC, USA, Release 6.11) K_m values were determined as 100.9µM for factor Xa/pefachrome-FXA and 81.6µM for trypsin/pefachrome-TRY. Inhibitor stock solutions were prepared at 40mM in Me2SO and tested at 500µM, 50µM and 5µM. Accuracy of Ki measurements was
- 30 confirmed by comparison with Ki values of known inhibitors of factor Xa and trypsin.

- In agreement with published data, benzamidine inhibited factor Xa, trypsin, thrombin, plasmin and urokinase with
- 35 Ki values of 155µM, 21µM, 330nM, 200nM and 100nM respectively. NAPAP inhibited thrombin with a Ki value of 3nM. Compounds of the invention were found to have

60142064-070299

activity in these assays.

Partial Thromboplastin Time Test Protocol

- 5 Venous blood was collected into 3.2% (0.109M) trisodium citrate vacutainer tubes at 1 volume of anticoagulant to nine volumes of blood. The blood cells were separated by centrifugation at 700g for ten minutes to yield plasma, which was frozen at 70°C until required.
- 10 To perform the test, 100 μ l of plasma was pipetted into in a glass test tube, 1 μ l of test compound in DMSO was added, and allowed to warm to 37° over two minutes. 100 μ l of warm (37°) Manchester (tissue thromboplasin) reagent (Helena Biosciences, UK) was added, allowed to
- 15 equilibrate for sixty seconds. 100 μ l of warm (37°) 25mM calcium chloride solution was added to initiate clotting. The test tube was tilted three times through a 90° angle every five seconds to mix the reagents and the time to clot formation recorded. Data from a series
- 20 of observations and test compound concentrations are analysed by a SAS statistical analysis program and a CT2 (Concentration required to double clotting time) for each compound is generated.
- 25 Compounds of the invention were found to significantly elongate the partial thromboplastin time.

Example No.	Conc. necessary to double the prothrombin time (μ M)
9	26
30 37	6.7
42	7.8
44	11
47	8.8
50	9.0
35 51	12

activity in these assays.

Partial Thromboplastin Time Test Protocol

- 5 Venous blood was collected into 3.2% (0.109m) trisodium citrate vacutainer tubes at 1 volume of anticoagulant to nine volumes of blood. The blood cells were separated by centrifugation at 700g for ten minutes to yield plasma, which was frozen at 70°C until required.
- 10 To perform the test, 100 μ l of plasma was pipetted into in a glass test tube, 1 μ l of test compound in DMSO was added, and allowed to warm to 37° over two minutes. 100 μ l of warm (37°) Manchester (tissue thromboplasin) reagent (Helena Biosciences, UK) was added, allowed to
- 15 equilibrate for sixty seconds. 100 μ l of warm (37°) 25mM calcium chloride solution was added to initiate clotting. The test tube was tilted three times through a 90° angle every five seconds to mix the reagents and the time to clot formation recorded. Data from a series
- 20 of observations and test compound concentrations are analysed by a SAS statistical analysis program and a CT2 (Concentration required to double clotting time) for each compound is generated.
- 25 Compounds of the invention were found to significantly elongate the partial thromboplastin time.

Example No.	Conc. necessary to double the prothrombin time (μ M)
9	26
30 37	6.7
42	7.8
44	11
47	8.8
50	9.0
35 51	12

52

12

Compounds of the invention were found to be potent inhibitors of factor Xa.

5

Example 63.

4-Methylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.65 (3H, m); 7.50 (2H, m); 7.35 (5H, m);
10 6.60 (2H, d); 6.05 (1H, s); 3.30 (3H, s); 3.00-2.50
(8H, m); 2.80 (3H, s). MS TOF 525 (M+1⁺). Hplc (Magellan
C8, Gradient 3, water/acetonitrile/TFA) rt 13.17 min.

Example 64.

15 **3-Methyl-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide**

¹H nmr (CD₃CN) 7.90 (1H, s); 7.85 (1H, s); 7.80 (1H, s);
7.55 (6H, m); 6.25 (1H, s); 3.45 (3H, s); 3.00-2.50
(8H, m); 2.60 (3H, s). MS TOF 545 (M+1⁺). Hplc (Magellan
20 C8, Gradient 3, water/acetonitrile/TFA) rt 16.39 min.

Example 65.

4-Vinylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

25 ¹H nmr (CD₃CN) 7.75 (2H, d); 7.60 (1H, m); 7.45 (4H, m);
7.35 (5H, m); 6.75 (1H, m); 6.05 (1H, s); 5.90 (1H, d);
5.30 (1H, d); 3.00-2.50 (8H, m); 2.80 (3H, s). MS TOF
522 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 15.45 min.

30

Example 66.

3-Amino-4-hydroxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

35 ¹H nmr (CD₃CN) 7.60 (1H, m); 7.50-7.10 (9H, m); 7.35
(1H, d); 5.95 (1H, s); 3.25 (3H, s); 3.00-2.50 (8H, m).
MS TOF 527 (M+1⁺). Hplc (Magellan C8, Gradient 2,
water/acetonitrile/TFA) rt 15.46 min.

Example 67.

4-Methylthiobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.85 (2H, d); 7.80 (1H, m); 7.60 (2H, m);
5 7.50 (5H, m); 7.40 (2H, d); 6.15 (1H, s); 3.40 (3H, s);
3.10-2.70 (8H, m); 2.60 (3H, s). MS TOF 542 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
16.67 min.

Example 68.

3 Carboxamidobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 8.25 (1H, s); 7.95 (2H, d); 7.70 (1H, m);
7.55 (3H, m); 7.40 (5H, m); 6.05 (1H, s); 3.30 (3H,
15 s); 3.00-2.50 (8H, m). MS TOF 539 (M+1⁺). Hplc (Magellan
C8, Gradient 3, water/acetonitrile/TFA) rt 12.83 min.

Example 69.

3-Amino-4-methylcarboxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.90 (1H, d); 7.70 (1H, m); 7.55 (2H, m);
20 7.45 (5H, m); 7.20 (1H, s); 6.95 (1H, d); 6.05 (1H, s);
3.80 (3H, s); 3.30 (3H, s); 3.00-2.50 (8H, m). MS TOF
569 (M+1⁺). Hplc (Magellan C8, Gradient 3,
25 water/acetonitrile/TFA) rt 14.49 min.

Example 70.

3-Methyl-4-bromobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.65 (3H, m); 7.45 (3H, m); 7.30 (5H, m);
30 6.00 (1H, s); 3.25 (3H, s); 3.00-2.50 (8H, m); 2.40
(3H, s). MS TOF 589 (M+1⁺). Hplc (Magellan C8, Gradient
3, water/acetonitrile/TFA) rt 16.67 min.

Example 71.

4-Ethoxybenzoyl-D-phenylglycin -N-(4-fluoro-2-methyl
sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 7.75 (2H, d); 7.60 (1H, m); 7.50 (2H, m);
5 7.35 (5H, m); 6.85 (2H, d); 6.00 (1H, s); 4.00 (2H,
m); 3.20 (3H, s); 3.00-2.50 (8H, m); 1.30 (3H, t). MS
TOF 540 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 16.58 min.

10 Example 72.

5-Indoloyl-D-phenylglycine-N-(4-fluoro-2-methyl
sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 8.15 (1H, s); 7.95 (1H, m); 7.65 (2H, m);
7.60-7.35 (7H, m); 6.60 (1H, s); 6.10 (1H, s); 3.30
15 (3H, s); 3.00-2.60 (8H, m). MS TOF 535 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
13.88 min.

Example 73.

20 5 Benzamidazoyl-D-phenylglycine-N-(4-fluoro-2-methyl
sulphonylphenyl)piperazinamide

¹H nmr (CD₃CN) 8.75 (1H, s); 8.25 (1H, s); 7.75 (2H, m);
7.60 (1H, m); 7.50 (2H, m); 7.35 (5H, m); 6.60 (2H, d);
6.05 (1H, s); 3.30 (3H, s); 3.00-2.50 (8H, m). MS TOF
25 536 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 10.08 min.

Example 74.

30 3-Aminobenzoyl-D-phenylglycine-1'-methyl-
4,4'bispiperidinamide

¹H nmr (CD₃CN) a mixture of conformers only one recorded
here 7.65 (1H, m); 7.35 (5H, m); 7.05 (1H, m); 6.95
(2H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30
(2H, m); 2.90-2.40 (8H, m); 2.55 (3H, s); 1.60 (2H, m);
35 1.30 (2H, m); 1.00 (2H, m). MS TOF 435 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
7.65 min.

662020-49024TOS

Example 75.

3-Amino-4-chlorobenzoyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide

¹H nmr (CD₃CN) a mixture of conformers only one recorded
5 here 7.75 (1H, m); 7.30 (5H, m); 7.20 (1H, m); 6.95
(1H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30
(2H, m); 2.90-2.40 (8H, m); 2.55 (3H, s); 1.60 (2H, m);
1.30 (2H, m); 1.00 (2H, m). MS TOF 469 (M+1⁺). Hplc
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
10 9.58 min.

Example 76.

3-Amino-4-methylbenzoyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide

¹H nmr (CD₃CN) a mixture of conformers only one recorded
15 here 7.75 (1H, m); 7.35 (5H, m); 7.05 (2H, m); 5.85
(1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-
2.40 (8H, m); 2.65 (3H, s); 2.15 (3H, s); 1.60 (2H, m);
1.30 (2H, m); 1.00 (2H, m). MS TOF 449 (M+1⁺). Hplc
20 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt
8.03 min

Example 77.

3-Aminonaphth-2-oyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide

¹H nmr (CD₃CN) a mixture of conformers only one recorded
25 here 7.95 (1H, m); 7.65 (1H, d); 7.45 (2H, m); 7.30
(5H, m); 7.15 (1H, m); 6.95 (1H, s) 5.95 (1H, s); 4.45
(1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m);
30 2.65 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m).
MS TOF 485 (M+1⁺). Hplc (Magellan C8, Gradient 3,
water/acetonitrile/TFA) rt 9.94 min.

002040-49024T09